Verastem (VSTM) Expected to Announce Quarterly Earnings on Thursday

Verastem (NASDAQ:VSTM) is projected to issue its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.46) per share and revenue of $21.4280 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Verastem (NASDAQ:VSTM) last posted its earnings results on Wednesday, March 4th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.01). The company had revenue of $17.54 million during the quarter, compared to the consensus estimate of $16.85 million. On average, analysts expect Verastem to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Verastem Stock Down 1.2%

Verastem stock traded down $0.07 during trading hours on Tuesday, hitting $5.88. 411,176 shares of the stock traded hands, compared to its average volume of 1,957,286. The company has a current ratio of 3.09, a quick ratio of 3.07 and a debt-to-equity ratio of 1.33. The firm’s 50-day moving average price is $5.74 and its two-hundred day moving average price is $7.21. Verastem has a one year low of $4.01 and a one year high of $11.24. The company has a market cap of $516.41 million, a PE ratio of -1.83 and a beta of 0.34.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on VSTM. BTIG Research reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Verastem in a report on Monday, April 20th. Mizuho set a $18.00 price objective on Verastem in a research note on Thursday, February 19th. Wall Street Zen cut Verastem from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Verastem in a report on Monday, April 20th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $15.00 price objective (down from $19.00) on shares of Verastem in a report on Monday, March 30th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $16.60.

Hedge Funds Weigh In On Verastem

Several institutional investors and hedge funds have recently bought and sold shares of the company. Verition Fund Management LLC purchased a new stake in shares of Verastem during the third quarter valued at $1,252,000. XTX Topco Ltd raised its position in shares of Verastem by 168.1% in the fourth quarter. XTX Topco Ltd now owns 131,121 shares of the biopharmaceutical company’s stock worth $1,012,000 after acquiring an additional 82,210 shares during the period. Burkehill Global Management LP acquired a new position in shares of Verastem in the fourth quarter worth about $965,000. Deutsche Bank AG raised its position in shares of Verastem by 18.8% in the fourth quarter. Deutsche Bank AG now owns 45,570 shares of the biopharmaceutical company’s stock worth $352,000 after acquiring an additional 7,213 shares during the period. Finally, VARCOV Co. acquired a new position in shares of Verastem during the 4th quarter worth about $261,000. 88.37% of the stock is owned by hedge funds and other institutional investors.

About Verastem

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.